The two strategies, used to reduce renal, brain, and heart injury after surgery, were ineffective, but the story isn’t done.

Part II of this 7,000-patient trial suffered from discontinuations and low event rates: still, early MRA did not impact CV ...

CHICAGO, IL—Following bioprosthetic valve surgery, anticoagulation with edoxaban (Savaysa; Daiichi Sankyo) is as effective as ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

CHICAGO, IL—For patients with a history of acute MI who are vulnerable to the cardiovascular risks posed by influenza ...

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.

Clinicians typically first turn to antiarrhythmic drugs, but switching up the order may be offer patients better outcomes.

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.

CHICAGO, IL—Giving rivaroxaban (Xarelto; Bayer/Janssen) to adults under the age of 65, after an atrial fibrillation (AF) ...

Total and LDL cholesterol variability over time may be a biomarker for higher dementia risk and cognitive decline.

COVID-19 “magnified” preexisting disparities for rural patients as compared with their urban counterparts, one study author ...

Ami Bhatt asks Kate Dalton to share details on the challenges of early feasibility studies from her perspective as a clinical site coordinator.